AVCT
NEUTRALAvacta Group Announces Investor Webinar
The life sciences company is hosting an investor webinar to discuss recent data presentations on its proprietary drug candidates.
Avacta Group
34.50GBX
1.47%
Market Cap
133.52M
Volume
700.29k
36% of avg
P/E Ratio
-0.04
EPS (TTM)
-9.46
Beta
-0.17
Day Range
33.77p - 36.00p
52 Week Range
28.83p34.50p86.40p
34.50p
Upcoming Events
AVCT
NEUTRALAvacta Announces Board Change
The healthcare company announces the retirement of a non-executive director and the appointment of a new chair for the Remuneration Committee.
AVCT
NEUTRALAvacta presents preclinical data on FAP-EXd candidate at AACR
The biotechnology company presents preclinical data on its FAP-EXd candidate and insights on the pre|CISION platform at the AACR Annual Meeting.
AVCT
NEUTRALAvacta Presents Promising Phase 1 Data for Lead Cancer Drug Candidate
The biotechnology company reports positive early-stage trial data for its lead cancer drug candidate, highlighting signs of efficacy and a favorable safety profile.
AVCT
NEUTRALAvacta Raises Funds to Settle Convertible Bond Obligations
The biotechnology company is issuing new shares to settle quarterly payments on its convertible bond, maintaining cash for its drug development pipeline.
AVCT
NEUTRALAvacta Provides Quarterly Update on Pipeline Progress
The biotechnology company updates on the progress of its pipeline, including the advancement of its FAP-Dox and FAP-EXd drug candidates.
AVCT
NEUTRALAvacta to Present at AACR Annual Meeting
The biotechnology company will have three presentations at the upcoming AACR Annual Meeting, showcasing data from its proprietary pre|CISION platform and pipeline of peptide drug conjugates.
AVCT
NEUTRALAvacta to Present at Leerink Healthcare Conference
The biotechnology company will present at an upcoming healthcare conference.
AVCT
GOODAvacta Advances Cancer Drug AVA6000 with Promising Early Data
The biotechnology company reports promising early data for its cancer drug AVA6000, with high disease control rates and favorable safety in Phase 1 trials.
AVCT
GOODAvacta Sharpens Focus on Therapeutics with Diagnostics Sale
The life sciences company is selling its UK diagnostics unit to become a pure-play therapeutics business, with proceeds to fund R&D on promising cancer drug candidates.